

[OFFICE LETTERHEAD]

[Date]

[Contact Name]

[Contact Title]

[Name of Insurance Company]

[Insurance Address]

Patient Name: **[Patient Name]**

Patient Date of Birth: **[Patient DOB]**

Policy Number: **[Policy Number]**

Group Number: **[Group Number]**

Case Number: **[Case Number]**

Re: Appeal for the Denial of CYSTARAN® (cysteamine ophthalmic solution) 0.44%

Dear appeal reviewer:

I am writing to request an APPEAL of the decision to deny CYSTARAN for my patient **[Patient name]**. **[Patient name]** has been diagnosed with cystinosis and requires treatment for corneal cystine crystals.

CYSTARAN (cysteamine ophthalmic solution) 0.44% is an FDA approved cystine-depleting agent indicated for the treatment of corneal cystine crystals in adults and children with cystinosis.¹

It is well documented in the literature that all patients with cystinosis will develop corneal crystals, and if topical treatment is stopped, crystals will return.¹ The oral systemic treatments do not have an impact on the cornea due to the avascular nature of the cornea, thereby requiring topical treatment.² This patient has documented corneal crystals as seen by **[exam type]** on **[date of exam]**.

Our office received a denial for CYSTARAN on **[date]**. In that denial, CYSTARAN was denied due to the following reasons:

[list reasons]

I find this decision to be inconsistent with the clinical evidence, and in my clinical judgement, treatment with CYSTARAN is medically necessary due to the following reasons:

[answer each reason why CYSTARAN was denied]

I would appreciate your prompt review of this appeal and reconsideration of approval of CYSTARAN for **[patient name]**.

If you have any questions or wish to conduct a Peer-to-Peer discussion, feel free to contact me at **[enter phone number]**.

Thank you for your time and consideration.

[First and Last name, credentials]

Resources:

1. CYSTARAN® (cysteamine ophthalmic solution) 0.44% [prescribing information]. Rockville, MD: Leadiant Biosciences, Inc.; Current Approved PI
2. Gahl, W et al. Cystinosis. *New England Journal of Medicine*. 2002; 347(2): 111-121